reviewed april 2026|next review october 2026|88 physicians psi has verified|10626 published studies
Vilon
Vilon is a synthetic dipeptide (lysyl-glutamic acid) from the Khavinson bioregulatory medicine program, classified as a thymic bioregulator proposed to restore age-related immune decline through epigenetic gene modulation.
Evidence landscape: 10626 published studies
10,626 published items (broad query). 22 human studies and 150 animal studies.
- 22 Human
- 150 Animal
- 28 Reviews
- 10426 Other research
Not FDA-approved. Not evaluated by any Western regulatory agency. Vilon is a research compound from the Khavinson bioregulatory medicine program in St. Petersburg, Russia.
Not available through Western pharmaceutical channels. Available through Russian supplement and research channels. Part of the Khavinson bioregulator series.
Vilon (Lys-Glu) is a synthetic dipeptide from the Khavinson program alongside epitalon (pineal), pinealon (brain), thymogen (thymus), vesugen (vascular), and others. The program proposes that short peptides interact with specific DNA sequences to restore age-related gene expression patterns.
PSI Assessment
The Khavinson bioregulatory medicine program has produced a series of short peptides, each claimed to target a specific organ system. Vilon (Lys-Glu) is the thymic bioregulator in this series, structurally related to thymogen (Glu-Trp), which targets the same organ. The program proposes that peptides as short as two amino acids can interact with specific DNA sequences to restore age-related gene expression patterns. Russian studies report immunostimulatory effects. The evidence comes predominantly from the St. Petersburg Institute of Bioregulation and Gerontology. Independent replication by Western research groups has not been published. Whether a dipeptide can achieve the tissue-specific gene regulation claimed is one of the most ambitious propositions in the program.
A two-amino-acid thymic bioregulator from the Khavinson program. Russian immunostimulation data. Evidence concentrated at a single research institute.
The proposed mechanism is epigenetic modulation of immune-related gene expression at the chromatin level. Vilon (Lys-Glu) is part of the Khavinson bioregulatory medicine program alongside epitalon (pineal), pinealon (brain), thymogen (thymus), vesugen (vascular), and others. The hypothesis is that short peptides interact with specific DNA sequences to restore age-related gene expression patterns. Russian studies report immunostimulatory effects. The evidence comes predominantly from the St. Petersburg Institute of Bioregulation and Gerontology.
What the evidence supports
Russian studies report immunostimulatory effects with vilon administration. The dipeptide structure (Lys-Glu) is characterized. The Khavinson bioregulatory medicine program has produced internally consistent data across the vilon research series.
What is not yet established
Independent replication outside the St. Petersburg Institute. Whether a dipeptide can selectively modulate thymic gene expression through epigenetic mechanisms. Whether vilon produces immunostimulation by Western clinical trial standards. Comparative efficacy against established immune modulators.
Research Evidence
The findings below cover vilon's proposed mechanism, the Russian clinical data, and the evidence limitations.
Evidence by condition
Evidence dimensions available for each condition Vilon has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Immunostimulation | ||||
| Aging Research | ||||
| Thymic Function |
Russian studies report immunostimulatory effects with vilon (Lys-Glu) administration, including modulation of T-lymphocyte subpopulation ratios in aged animal models.
The data comes predominantly from the St. Petersburg Institute of Bioregulation and Gerontology. Independent replication by Western research groups has not been published.
22 Human|150 Animal|28 Reviews
View all 10626 indexed studiesHow Vilon Works
Vilon (Lys-Glu) is a synthetic dipeptide from the Khavinson bioregulatory program. The proposed mechanism is epigenetic modulation of immune-related gene expression through direct peptide-DNA interaction at the chromatin level. This mechanism has not been independently validated.
A two-amino-acid peptide from the Khavinson program proposed to stimulate thymus function and restore immune cell production during aging.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Lys-Glu dipeptide. Proposed mechanism involves modulation of gene expression in thymic epithelial cells through direct peptide-DNA interaction. Data primarily from the Khavinson laboratory in St. Petersburg.
What is Vilon being studied for?
Researchers are studying Vilon across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Vilon overall. This means a compound can have human studies for one condition but only animal data for another.
Immunostimulation
·Animal StudiesRussian studies report immunostimulatory effects including modulation of T-lymphocyte subpopulation ratios in aged animal models. The Khavinson program has produced internally consistent data.
Limitations: No independent replication outside the St. Petersburg Institute. Whether the reported immune parameter changes are clinically meaningful is not established by Western standards.
Aging Research
·Animal StudiesVilon is proposed to restore age-related immune decline through thymic function restoration. Animal studies from the Khavinson program report improved immune parameters in aged subjects.
Limitations: All data from a single research program. No Western-standard aging intervention trials.
Thymic Function
·PreclinicalThe proposed mechanism is restoration of thymic gene expression through direct peptide-DNA interaction. Animal study data from the Khavinson laboratory.
Limitations: The claim that a dipeptide can achieve tissue-specific thymic gene regulation has not been independently validated. The mechanism is proposed but not confirmed by independent research.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not evaluated by any Western regulatory agency. Research compound from the Khavinson program.
Availability: Not available through Western pharmaceutical channels. Available in Russia through supplement channels.
Class context: Vilon is a Khavinson bioregulator dipeptide (Lys-Glu). As a simple dipeptide, it exhibits low toxicity in published studies. Independent Western safety assessment has not been conducted.
Vilon has been used in Russian clinical practice with no significant reported safety concerns. As a simple dipeptide, toxicity risk is expected to be low. Independent Western safety assessment has not been conducted.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Vilon discussion.
Comparison and Related Research
Vilon is part of the Khavinson bioregulatory program. The comparisons below clarify its position relative to other thymic peptides.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.A study examining how the KE dipeptide (vilon) modulates expression of key aging-related genes in human mesenchymal stem cells. The research found that vilon influenced SIRT1 and PARP1/PARP2 pathways, which are involved in DNA repair and cellular senescence, suggesting a mechanism for the peptide's proposed geroprotective effects.Khavinson VK et al., 2023 in Adv Gerontol. View on PubMed
- 2.An in vitro study evaluating the effects of short bioregulatory peptides, including KE (vilon), on inflammatory pathways in human monocyte-derived cells. The peptides modulated proliferation and cytokine production, providing mechanistic evidence for immunomodulatory activity at the cellular level.Avolio F et al., 2022 in Int J Mol Sci. View on PubMed
- 3.A clinical observation study from the Khavinson program reporting that elderly patients treated with thymic peptide preparations (including vilon as a synthetic analog of thymalin) showed reduced mortality over a multi-year follow-up period. The paper is a key reference for the broader bioregulatory peptide clinical framework.Khavinson VKh et al., 2003 in Neuro Endocrinol Lett. View on PubMed
- 4.A systematic review covering published evidence on short peptide-DNA interactions and gene expression regulation. The review included data on vilon (KE) alongside other bioregulatory peptides, cataloguing the evidence base for epigenetic mechanisms of action across the Khavinson peptide series.Khavinson VK et al., 2021 in Molecules. View on PubMed
- 5.A transcriptomic study examining how short peptides, including vilon (KE), modulate gene expression in aging human mesenchymal stem cells. The analysis identified changes in expression of genes associated with cell cycle regulation, inflammation, and extracellular matrix maintenance.Ashapkin V et al., 2020 in Mol Biol Rep. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.